Menu
FDA DECISION ·
Enhertu
fam-trastuzumab deruxtecan-nxki · Daiichi Sankyo
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
For adults with unresectable or metastatic HR-positive breast cancer with HER2-low (IHC 1+ or IHC 2+/ISH-negative) or HER2-ultralow (IHC 0 with membrane staining) disease on an FDA-approved test, after progression on at least one endocrine therapy in the metastatic setting.
LAMPGEN ANALYSIS
Why it matters
This action extended the indication to HER2-ultralow disease and moved treatment earlier for eligible endocrine-pretreated patients.
What research teams should watch
Ensure pathology reports distinguish faint membrane staining from no staining and that prior endocrine treatment is documented.
Related study operations checklist
See the staffing responsibilities, timing, and handoff questions for this study setting.
HER2-selected breast cancerPRIMARY RECORDS